Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    Nutmeg molecular structure

    Nutmeg Stats & Data

    Chemical Class Botanical preparation
    Psychoactive Class Psychedelic / Deliriant

    Pharmacology

    DrugBank

    Description

    Nutmeg allergenic extract is used in allergenic testing.

    Receptor Profile

    Receptor Actions

    Inhibitors
    FAAH inhibitor (indirect endocannabinoid modulation)
    MAGL inhibitor (indirect endocannabinoid modulation)
    Weak monoamine oxidase inhibitor
    Other
    Anticholinergic properties (high doses)

    History & Culture

    1500 BCE–13th century

    Nutmeg is native to the Banda Islands, a cluster of eleven small volcanic islands within the Maluku archipelago of eastern Indonesia. These remote islands remained the world's sole source of both nutmeg and mace until the mid-nineteenth century. Archaeological excavations on Pulau Ai have yielded potsherd residues dating back approximately 3,500 years, representing the earliest known evidence of nutmeg use. The spice circulated through Austronesian maritime trading networks from at least 1500 BCE. By the sixth century CE, nutmeg had spread westward to India and subsequently reached Constantinople. Arab merchants eventually traced the spice to its source in the Banda Islands by the thirteenth century, though they carefully concealed this information from European traders to maintain their commercial advantage.

    1511–1945

    European pursuit of nutmeg commenced following the Portuguese conquest of Malacca in August 1511. Shortly after securing this strategic trading hub, Afonso de Albuquerque dispatched a three-ship expedition under António de Abreu to locate the legendary spice islands. Malay pilots guided the fleet through Java and the Lesser Sundas, reaching Banda in early 1512. This marked the first European contact with the islands, where the expedition spent approximately one month acquiring nutmeg, mace, and cloves. The Portuguese apothecary Tomé Pires, stationed in Malacca from 1512 to 1515, documented these islands in his work Suma Oriental. However, Portugal never established permanent control over the trade. The Dutch East India Company waged a brutal campaign for monopoly over nutmeg production in 1621. The violence was catastrophic for the indigenous Bandanese population—historians estimate that of approximately 15,000 inhabitants, only around 1,000 survived, with the remainder killed, starved during flight, exiled, or sold into slavery. The Company subsequently constructed extensive plantation systems throughout the islands. During the Napoleonic Wars, British forces temporarily occupied the Banda Islands and transplanted nutmeg trees, along with their native soil, to Ceylon, Penang, Bencoolen, and Singapore. From these locations, cultivation spread to additional colonial territories including Zanzibar and Grenada. Dutch control of the Spice Islands persisted until the Second World War.

    Nutmeg has acquired symbolic importance in several regions shaped by its trade history. Grenada, which developed into a major producer following British colonial transplantation efforts, incorporated a stylized split-open nutmeg fruit into its national flag upon adoption in 1974. In the United States, Connecticut carries the nickname "the Nutmeg State," purportedly stemming from folklore about dishonest traders who carved wooden imitations to deceive buyers. The expression "wooden nutmeg" subsequently entered American vernacular as a general term for fraudulent merchandise. Beyond culinary applications, nutmeg has traditionally been consumed for its psychoactive and reputed aphrodisiac properties, though clinical evidence supporting these uses remains limited. Its widespread availability and low cost have led to recreational experimentation, particularly among adolescents, college students, and incarcerated individuals seeking inexpensive intoxication.

    Toxicity

    PsychonautWiki

    Myristicin is neurotoxic and can be fatal in extremely high doses. Also myristicin causes severe dehydration. It increases side effects of myristicin.

    Addiction & dependence

    Myristicin is not known to be addictive and the desire to use it can actually decrease with use. Information regarding tolerance is unknown.

    Effect Profile

    Curated + 320 Reports
    Psychedelic 6.2

    Strong visuals and auditory effects with moderate body load, low headspace

    Visual Intensity×3
    109.52.0
    Headspace Depth×3
    32.22.7
    Auditory Effects×1
    8104.0
    Body Load / Somatic Effects×1
    76.64.0
    Catalog Erowid BlueLight

    Empirical Duration

    Erowid Reports

    Median times after the dose that Erowid reports state. A curve is drawn only when reports state all four points (onset, peak begins, comedown begins, back to baseline) and the medians fall in that order. No point is estimated from another.

    Onset Come Up Peak Offset
    Oral (69 reports)

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans for myristicin; overall nutmeg intoxication persists 24–72 h reflecting slow kinetics and/or lingering pharmacodynamic effects rather than a defined single-compound half-life.
    Addiction Potential
    Low; not considered habit-forming. Repeated recreational use is uncommon due to long, dysphoric, and physiologically taxing effects.

    Tolerance Decay

    Baseline ~14d

    No controlled data on tolerance development; given the long duration and rare repeated recreational use, practical guidance is to allow at least 1–2 weeks between exposures to minimize cumulative physiological stress and residual impairment. Data quality: anecdotal/low.

    Experience Report Analysis

    Erowid BlueLight
    377 Reports
    305 Single-substance
    1992–2025 Date Range
    65 With Age Data
    29 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 320 experience reports (305 single-substance Erowid + 15 Bluelight)

    320 Reports
    88 Effects Detected
    35 Positive
    34 Adverse
    19 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

    Rows resting on fewer than 20 reports show a count (“3 of 7”) instead of a bar. Why 20?

    Positive Effects 35

    Music Enhancement 27.8% (95% interval 23 to 33 percent) 88%
    Color Enhancement 24.7% (95% interval 20 to 30 percent) 75%
    Stimulation 24.7% (95% interval 20 to 30 percent) 85%
    Euphoria 22.5% (95% interval 18 to 27 percent) 88%
    Body High 10.2% (95% interval 7 to 14 percent) 70%
    Focus Enhancement 8.8% (95% interval 6 to 12 percent) 80%
    Empathy 8.5% (95% interval 6 to 12 percent) 70%
    Tactile Enhancement 6.9% (95% interval 5 to 10 percent) 90%
    Introspection 3.8% (95% interval 2 to 6 percent) 82%
    Creativity Enhancement 3.2% (95% interval 2 to 6 percent) 80%
    Thought Acceleration 5 of 15 77%
    Vivid Dreams 3 of 15 88%
    Libido Enhancement 3 of 15 87%
    Hypersomnia 3 of 15 85%
    Auditory Echo 2 of 15 82%
    Joy 2 of 15 85%
    Mood Lift 2 of 15 82%
    Appetite Increase 2 of 15 80%
    Orgasm Enhancement 2 of 15 82%
    Contentment 2 of 15 85%

    Adverse Effects 34

    Anxiety 32.5% (95% interval 28 to 38 percent) 70%
    Nausea 27.8% (95% interval 23 to 33 percent) 80%
    Confusion 21.6% (95% interval 17 to 27 percent) 70%
    Headache 16.2% (95% interval 13 to 21 percent) 78%
    Memory Suppression 11.1% (95% interval 8 to 15 percent) 70%
    Motor Impairment 8.8% (95% interval 6 to 12 percent) 75%
    Increased Heart Rate 4.9% (95% interval 3 to 8 percent) 70%
    Muscle Tension 4.9% (95% interval 3 to 8 percent) 70%
    Pupil Dilation 4.4% (95% interval 3 to 7 percent) 86%
    Sweating 3.2% (95% interval 2 to 6 percent) 75%
    ⚠ Psychosis 1.6% (95% interval 1 to 4 percent) 70%
    Dry Mouth 9 of 15 88%
    Dizziness 4 of 15 79%
    Body Load 3 of 15 82%
    Chills 2 of 15 78%
    Tremor 2 of 15 75%
    Hot Flashes 2 of 15 85%
    Libido Suppression 1 of 15 75%
    Social Anxiety 1 of 15 80%
    Vomiting 1 of 15 75%
    Show 14 more adverse effects
    Dysphoria 1 of 15 75%
    Perceived Inanimate Transformation 1 of 15 75%
    Itching 1 of 15 70%
    Frequent Urination 1 of 15 75%
    Insomnia 1 of 15 75%
    Muscle Twitching 1 of 15 70%
    Body Temperature Change 1 of 15 85%
    Panic 1 of 15 90%
    Paranoia 1 of 15 90%
    Blurred Vision 1 of 15 80%
    Constipation 1 of 15 75%
    Muscle Spasm 1 of 15 70%
    Emotional Blunting 1 of 15 70%
    Stomach Cramps 1 of 15 85%
    Show 19 neutral or unclassified mentions
    Sedation 41.3% (95% interval 36 to 47 percent)
    Visual Distortions 29.5% (95% interval 25 to 35 percent)
    Auditory Effects 25.3% (95% interval 21 to 30 percent)
    Closed-Eye Visuals 12.8% (95% interval 10 to 17 percent)
    Open-Eye Visuals 12.8% (95% interval 10 to 17 percent)
    Dissociation 12.5% (95% interval 9 to 17 percent)
    Hospital 7.9% (95% interval 5 to 11 percent)
    Time Distortion 2.6% (95% interval 1 to 5 percent)
    Depersonalization 3 of 15
    Focus Suppression 3 of 15
    Time Dilation 2 of 15
    Body Distortion 1 of 15
    Numbness 1 of 15
    Flushing 1 of 15
    Heaviness 1 of 15
    Thought Disorganization 1 of 15
    Appetite Suppression 1 of 15
    Drowsiness 1 of 15
    Thought Deceleration 1 of 15

    Also reported in combinations. In the 72 Nutmeg reports where another drug was taken too, 6 (8.3%) mention hospital, emergency services or an overdose, 1 (1.4%) a seizure and 4 (5.6%) psychosis. In the 305 single-substance reports: 7.9%, 0.7% and 1.6%. These are not in the figures above: they cannot be put down to Nutmeg alone, and a mention is not always something that happened to the writer.

    Subjective Effect Ontology

    Experience Reports

    Structured effect tags extracted from 392 Erowid & Bluelight experience reports using a controlled vocabulary of 220+ canonical effects across 15 domains.

    Auditory

    music enhancement 126 32.1% (95% interval 28 to 37 percent) auditory distortions 101 26.8% (95% interval 23 to 32 percent)

    Emotional

    anxiety 122 32.4% (95% interval 28 to 37 percent) euphoria 102 26.0% (95% interval 22 to 31 percent)

    Gastrointestinal

    nausea 123 31.4% (95% interval 27 to 36 percent)

    Motor

    sedation 168 42.8% (95% interval 38 to 48 percent) stimulation 107 27.3% (95% interval 23 to 32 percent)

    Visual

    visual distortions 125 33.2% (95% interval 29 to 38 percent)

    8 unique effects extracted · Derived from Erowid & Bluelight reports

    Dosage Distribution

    Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.

    Median: 15000.0 mg IQR: 10000.0–21000.0 mg n=90

    3 reports gave a dose above the typical range (65,000–70,000 mg), so they are not in the figures above. 1 of them mentions hospital, emergency services or an overdose. Listing a dose here does not mean it is safe.

    Show the reports

    Real-World Dose Distribution

    Erowid

    From 130 of 448 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

    Oral (n=130)

    Median: 15500.0mg 25th: 10000.0mg 75th: 22000.0mg 90th: 30000.0mg

    Common Combinations

    Most co-occurring substances, as a share of all 377 reports filed under Nutmeg; whiskers are 95% intervals

    Form / Preparation

    Most common forms and preparations, as a share of the 300 reports that give one; whiskers are 95% intervals

    Body-Weight Dosing

    Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

    Median: 216.868 mg/kg IQR: 149.51–298.98 mg/kg n=86

    2 reports gave a dose above the typical range (895.317–928.571 mg/kg), so they are not in the figures above. 1 of them mentions hospital, emergency services or an overdose. Listing a dose here does not mean it is safe.

    Show the reports

    Redose Patterns

    Redosing behavior across 311 reports

    12.9% (95% interval 10 to 17 percent) Redosed
    1.2 Avg Doses
    60m Median Interval

    Harm Reduction

    drugs.wiki

    Key harm-reduction considerations and rationale (evidence lines include summaries from clinical/animal toxicology, case compilations, and large experience repositories): 1) Delayed onset with very long duration raises redosing and impairment risks — effects often begin 2–7 h after ingestion, peak near 8–12 h, and can last 24–36 h with after-effects up to 72 h, so redosing within the first 8–12 h substantially increases the chance of severe dysphoria and toxic effects; driving or operating machinery should be avoided for at least the remainder of the day and often the next day. 2) Potency varies widely between seeds and powders; essential oil is far more concentrated — composition differences (myristicin, elemicin, safrole, terpenes) and storage/freshness lead to unpredictable strength; pre-ground supermarket spice can be weaker or stale, while fresh whole seed and essential oil can be much stronger; essential oil ingestion has been associated with more severe toxicity (including seizures) and is not recommended. 3) Clinical toxidrome commonly includes anticholinergic-like symptoms (dry mouth, blurred vision, urinary retention), tachycardia, flushing, agitation, confusion, and sometimes paranoia or frank delirium; management is supportive and effects usually resolve within 24–48+ h. 4) Historical and toxicology sources implicate allylbenzenes; myristicin itself is a major component of nutmeg/mace oils; myristicin’s exact contribution to human psychotropic effects remains uncertain, but toxicology programs studied it because of broad exposure and structural similarity to other flavoring alkenylbenzenes with toxic potential in rodents. 5) Pregnancy/lactation: avoid doses above culinary use — nutmeg/mace oils are GRAS for food amounts, but high doses can produce anticholinergic symptoms and there is historical concern for abortifacient potential; LactMed advises avoiding amounts above flavoring doses during breastfeeding. 6) Liver prudence: while myristicin’s carcinogenicity in humans is unproven, related alkenylbenzenes (e.g., safrole, methyleugenol) show hepatotoxic/carcinogenic signals in rodents; avoid combining large nutmeg doses with alcohol or other hepatotoxic exposures and avoid repeated use. 7) Practical HR: weigh doses with a scale; start low on a separate day with nothing else onboard; do not redose the same day; plan a low-stimulus setting, temperature control, and passive hydration (small, regular sips; avoid extreme over- or underhydration); monitor for chest pain, fever, severe confusion, seizures, or urinary retention — seek urgent care if these occur; avoid in children and in people with cardiovascular disease, urinary retention history, glaucoma, severe psychiatric vulnerability, or pregnancy.

    Evidence/citations supporting the above points are listed in the citations field.

    ← Back to Nutmeg